| name | es-hcm-ugps6-mg-phos-monitor |
| description | The guideline suggests checking serum magnesium and phosphate levels and repleting if low in patients receiving antiresorptive therapy for hypercalcemia of malignancy. Clinicians should consider this when they note electrolyte abnormalities or inquire about supportive care during bisphosphonate or denosumab treatment. |
Monitor and replete serum magnesium and phosphate if low during HCM treatment
STEP 1 — Gather Information
Obtain serum magnesium and phosphate levels in adults with hypercalcemia of malignancy who are receiving or about to receive antiresorptive therapy (IV bisphosphonate or denosumab). Document baseline renal function and current medications that may affect electrolytes.
STEP 2 — Rule In / Rule Out
Compare results to laboratory reference ranges: low if magnesium <1.7 mg/dL or phosphate <2.5 mg/dL; normal if at or above these thresholds. Proceed to stratification if either is low.
STEP 3 — Classify or Stratify
If low, classify deficiency severity: mild (Mg 1.4-1.6 mg/dL or PO4 2.0-2.4 mg/dL), moderate (Mg 1.0-1.3 mg/dL or PO4 1.5-1.9 mg/dL), severe (<1.0 mg/dL Mg or <1.5 mg/dL PO4). If normal, continue routine monitoring.
STEP 4 — Decide
For mild deficiency, initiate oral replacement (e.g., magnesium oxide 400 mg daily, phosphate supplement 250-500 mg daily) and recheck in 24-48 hours; for moderate/severe, consider IV replacement under cardiac monitoring and recheck every 12-24 hours until normal; if normal, maintain antiresorptive therapy and repeat electrolytes per institutional protocol.
Clinical Guardrails / Mimics / Pitfalls
Avoid rapid IV magnesium or phosphate infusion in patients with renal insufficiency to prevent hypermagnesemia, hyperphosphatemia, or ectopic calcification; do not replace if serum calcium is rising concurrently without reassessing HCM control; monitor for diarrhea with oral magnesium salts.
Concrete Clinical Example
A 62-year-old woman with lung cancer–related HCM on zoledronic acid reports fatigue; labs show Mg 1.4 mg/dL (low) and PO4 2.0 mg/dL (low). She receives oral magnesium glycinate 500 mg BID and sodium phosphate 500 mg TID; levels normalize after 48 hours; antiresorptive therapy continues without interruption.
Source: Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2023, https://doi.org/10.1210/clinem/dgac621
